BRCA2 and cancer: The paradigmatic example of this concept is the synthetic lethality between loss of breast cancer susceptibility 1–2 (BRCA1-BRCA2) in cancer and poly-ADP ribose polymerase (PARP) inhibitors (PARPi) [1].